Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2018-03-20
2018-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The metabolic disorder in diabetics may be reversible.Thus, it may be possible to restore physical ability by restoring the musculoskeletal system.Therefore, the diagnosis of sarcopenia if made can lead to interventions which may prevent the deterioration of body composition and the subsequent deterioration of quality of life. According to the results of the aforementioned studies it is still inconclusive if the metabolic disorder in diabetes may be related to sarcopenia, or sarcopenia may be a consequence of diabetes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
diabetes mellitus type 2
36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
WHOLE BODY DXA
Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
CONTROLS
14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
WHOLE BODY DXA
Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WHOLE BODY DXA
Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* confirmation criteria of a T2DM diagnosis were glycosylated hemoglobin A1c levels ≥ 6.5% and fasting plasma glucose ≥ 126 mg/dl (7 mmol/l).
Exclusion Criteria
* a malignant tumor, liver disease, end stage chronic kidney disease, a thyroid disorder, carpal tunnel syndrome,
* subjects who received special dietary supplements such as protein powder, during the last three months were excluded from the study.
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Thessaly
OTHER
Dionyssiotis, Yannis, M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yannis Dionyssiotis
Post graduate student in Hellenic Open University of Greece
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yannis Dionyssiotis, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Foundation for Care of Neurological Illnesses, Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foundation for Care of Neurological Illnesses, Greece
Athens, Attica, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dionyssiotis Y. Sarcopenia in the Elderly. Eur Endocrinol. 2019 Apr;15(1):13-14. doi: 10.17925/EE.2019.15.1.13. Epub 2019 Apr 12.
Dionyssiotis Y, Kapsokoulou A, Samlidi E, Angoules AG, Papathanasiou J, Chronopoulos E, Kostoglou-Athanassiou I, Trovas G. Sarcopenia: From definition to treatment. Hormones (Athens). 2017 Oct;16(4):429-439. doi: 10.14310/horm.2002.1764. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EAPDionyssiotis
Identifier Type: -
Identifier Source: org_study_id